Article

Direct inhibitors of InhA with efficacy similar or superior to isoniazid in novel drug regimens for tuberculosis

2024-03-14

Abstract excerpt

<h4>ABSTRACT</h4> Isoniazid is an important first-line medicine to treat tuberculosis (TB). Isoniazid resistance increases the risk of poor treatment outcomes and development of multidrug resistance, and is driven primarily by mutations involving katG , encoding the pro-drug activating enzyme, rather than its validated target, InhA. The chemical tractability of InhA has fostered efforts to discover direct inhibi...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 6dd97174-aa0d-59ca-9fb3-0e09e74de288
DOI: 10.1101/2024.03.08.584126

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Direct inhibitors of InhA with efficacy similar or superior to isoniazid in novel drug regimens for tuberculosisDOI 10.1101/2024.03.08.584126Read

Antitubercular drugs for an old target: GSK693 as a promising InhA direct inhibitor.Semantic proximity Read

Unlocking InhA: Novel approaches to inhibit Mycobacterium tuberculosis.Semantic proximity Read

Biological and Biochemical Evaluation of Isatin-Isoniazid Hybrids as Bactericidal Candidates against Mycobacterium tuberculosis.Semantic proximity Read

Overview on mechanisms of isoniazid action and resistance in Mycobacterium tuberculosis.Semantic proximity Read

Biological Profiling Enables Rapid Mechanistic Classification of Phenotypic Screening Hits and Identification of KatG Activation-Dependent Pyridine Carboxamide Prodrugs With Activity Against Mycobacterium tuberculosis.Semantic proximity Read

New and Old Hot Drug Targets in TuberculosisSemantic proximity Read

Exploring natural products library to identify potential inhibitors targeting isoniazid-resistant tuberculosis.Semantic proximity Read

Mutations in <i>rv0678</i> confer low-level resistance to benzothiazinone DprE1 inhibitors in <i>M. tuberculosis</i>Semantic proximity Read

Development of a Novel Lead that Targets M. tuberculosis Polyketide Synthase 13Semantic proximity Read

Development of amidase-dependent pyrazinoic acid prodrugs with activity against pyrazinamide resistant <i>Mycobacterium tuberculosis</i>Semantic proximity Read

Pretomanid resistance: An update on emergence, mechanisms and relevance for clinical practiceSemantic proximity Read

Discovery of new diaryl ether inhibitors against Mycobacterium tuberculosis targeting the minor portal of InhA.Semantic proximity Read